BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28599954)

  • 21. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
    Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
    Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.
    Chanouzas D; Small A; Borrows R; Ball S
    PLoS One; 2018; 13(3):e0193968. PubMed ID: 29558479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.
    Sester M; Sester U; Gärtner BC; Girndt M; Meyerhans A; Köhler H
    J Am Soc Nephrol; 2002 Oct; 13(10):2577-84. PubMed ID: 12239248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation.
    Cummins NW; Deziel PJ; Abraham RS; Razonable RR
    Transpl Infect Dis; 2009 Feb; 11(1):20-7. PubMed ID: 18811629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of age and cytomegalovirus on CD8
    Cantisán S; Páez-Vega A; Santos F; Rodríguez-Benot A; Aguado R; Rivero A; Montejo M; Torre-Cisneros J; Solana R;
    Exp Gerontol; 2017 Sep; 95():98-106. PubMed ID: 28465043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation.
    Espigado I; de la Cruz-Vicente F; BenMarzouk-Hidalgo OJ; Gracia-Ahufinger I; Garcia-Lozano JR; Aguilar-Guisado M; Cisneros JM; Urbano-Ispizua A; Perez-Romero P
    Transpl Int; 2014 Dec; 27(12):1253-62. PubMed ID: 25070273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
    Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
    Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.
    Chiereghin A; Gabrielli L; Zanfi C; Petrisli E; Lauro A; Piccirilli G; Baccolini F; Dazzi A; Cescon M; Morelli MC; Pinna AD; Landini MP; Lazzarotto T
    Transplant Proc; 2010; 42(1):69-73. PubMed ID: 20172283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study.
    Jacobs SE; Ibrahim U; Vega AB; Lagdameo J; Callahan J; Govindarajulu U; Gitman M; Levine JE; Rana M; Keyzner A
    Transpl Infect Dis; 2024 Jun; 26(3):e14290. PubMed ID: 38708941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.
    Favi E; Santangelo R; Iesari S; Morandi M; Marcovecchio GE; Trecarichi EM; Salerno MP; Ferraresso M; Citterio F; Romagnoli J
    Transplant Proc; 2017 Oct; 49(8):1766-1772. PubMed ID: 28923622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T; Stein M; Reinke P
    Transplantation; 2017 Oct; 101(10):e315-e325. PubMed ID: 28594749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
    El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
    J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients.
    Shlobin OA; West EE; Lechtzin N; Miller SM; Borja M; Orens JB; Dropulic LK; McDyer JF
    J Immunol; 2006 Feb; 176(4):2625-34. PubMed ID: 16456025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-transplant assessment of CMV-specific immune response by Elispot assay in kidney transplant recipients.
    Rittà M; Costa C; Sidoti F; Ballocco C; Ranghino A; Messina M; Biancone L; Cavallo R
    New Microbiol; 2015 Jul; 38(3):329-35. PubMed ID: 26147141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CMV drives the expansion of highly functional memory T cells expressing NK-cell receptors in renal transplant recipients.
    Makwana N; Foley B; Fernandez S; Lee S; Irish A; Pircher H; Price P
    Eur J Immunol; 2017 Aug; 47(8):1324-1334. PubMed ID: 28586095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
    Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
    Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ
    Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.
    Giulieri S; Manuel O
    Expert Rev Mol Diagn; 2011 Jan; 11(1):17-25. PubMed ID: 21171917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.